Advertisement

HNO

pp 1–17 | Cite as

Therapie des kutanen malignen Melanoms im Kopf-Hals-Bereich

Ein Update
  • B. Frerich
CME
  • 14 Downloads

Zusammenfassung

In den letzten Jahren hat es erhebliche Entwicklungen in der Behandlung des malignen Melanoms gegeben. Diese betreffen einerseits die durch Ergebnisse randomisierter Studien in ihrer Evidenz vergleichsweise gut abgesicherten Empfehlungen zur chirurgischen Resektion und zum Lymphknotenmanagement. Andererseits haben medikamentöse Neuentwicklungen wie die zielgerichteten Therapien zu umwälzenden Fortschritten in der Behandlung der metastasierten Stadien geführt. Die Kenntnis der Behandlungsalgorithmen und ihrer Aktualisierungen ist für den MKG-Chirurgen unabdingbar. Die S3-Leitlinie „Diagnostik, Behandlung und Nachsorge des malignen Melanoms“ wurde im Jahr 2013 veröffentlicht und inzwischen zweimal, 2016 und 2018 aktualisiert. Der vorliegende Beitrag informiert über diese Entwicklungen und deren aktuellen Stand und geht auf die für die Therapie des Melanoms im Kopf-Hals-Bereich relevanten Punkte ein.

Schlüsselwörter

Hauttumoren Sicherheitsabstand Sentinel-Lymphknoten-Biopsie Neck Dissection Zielgerichtete Therapie Immuntherapie 

Treatment of cutaneous malignant melanoma in the head and neck region

An update

Abstract

Major progress has been made in the treatment of malignant melanoma during recent years. On the one hand, reliable evidence-based recommendations regarding surgical resection as well as lymph node management have been established on the basis of results from randomized multicenter studies. On the other hand, the advent of targeted therapies has led to spectacular improvements in the treatment of metastasized melanomas. Knowledge concerning treatment algorithms and updates thereof is also essential for maxillofacial surgeons. The German S3 guideline on diagnosis and treatment of melanoma was published in 2013 and revised in 2016 and 2018. This article informs readers about these developments and addresses the items relevant for treatment of head and neck melanomas in particular.

Keywords

Skin neoplasms Resection margins Sentinel lymph node biopsy Neck dissection Targeted therapy Immunotherapy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

B. Frerich gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.

Literatur

  1. 1.
    de Giorgi V, Rossari S, Gori A, Grazzini M, Savarese I, Crocetti E, Cervadoro E, Massi D (2012) The prognostic impact of the anatomical sites in the „head and neck melanoma“: scalp versus face and neck. Melanoma Res 22:402–405CrossRefGoogle Scholar
  2. 2.
    Fadaki N, Li R, Parrett B, Sanders G, Thummala S, Martineau L, Cardona-Huerta S, Miranda S, Cheng ST, Miller JR 3rd, Singer M, Cleaver JE, Kashani-Sabet M, Leong SP (2013) Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome? Ann Surg Oncol 20:3089–3097CrossRefGoogle Scholar
  3. 3.
    Al Ghazal P, Gutzmer R, Satzger I, Starz H, Bader C, Thoms KM, Mitteldorf C, Schon MP, Kapp A, Bertsch HP, Kretschmer L (2014) Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node-negative patients limit the prognostic value of sentinel node biopsy for head or neck melanomas. Melanoma Res 24:158–164CrossRefGoogle Scholar
  4. 4.
    Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z, Royce T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L, Teague J, Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR, Futreal PA, Stratton MR (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191–196CrossRefGoogle Scholar
  5. 5.
    Nelemans PJ, Groenendal H, Kiemeney LA, Rampen FH, Ruiter DJ, Verbeek AL (1993) Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect 101:252–255CrossRefGoogle Scholar
  6. 6.
    Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2016) S3-Leitlinie Prävention von Hautkrebs. Version 1.1, AWMF Registernummer: 032/052OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/hautkrebs-praevention/. Zugegriffen: 5. Jan. 2018Google Scholar
  7. 7.
    Robert Koch-Institut (Hrsg) (2017) Krebs in Deutschland für 2013/2014, 11. Ausgabe, Berlin. www.krebsdaten.de. Zugegriffen: 27. Dez. 2017Google Scholar
  8. 8.
    Gemeinsames Krebsregister (Hrsg) (2015) Krebsinzidenz und Krebsmortalität 2009–2012 (Jahresbericht) Berlin.Google Scholar
  9. 9.
    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr., Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206CrossRefGoogle Scholar
  10. 10.
    Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2016) S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms. Langversion 2.0, AWMF Registernummer: 032/024OL. http://leitlinienprogramm-onkologie.de/Melanom.65.0.html. Zugegriffen: 27. Dez. 2017Google Scholar
  11. 11.
    Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI et al (2017) Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472–492CrossRefGoogle Scholar
  12. 12.
    Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, Colman MH, Zhang Y (2003) Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 97:1488–1498CrossRefGoogle Scholar
  13. 13.
    Egger ME, Callender GG, McMasters KM, Ross MI, Martin RC 2nd, Edwards MJ, Urist MM, Noyes RD, Sussman JJ, Reintgen DS, Stromberg AJ, Scoggins CR (2013) Diversity of stage III melanoma in the era of sentinel lymph node biopsy. Ann Surg Oncol 20:956–963CrossRefGoogle Scholar
  14. 14.
    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr., Morton DL, Ross MI, Sondak VK (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452–2459CrossRefGoogle Scholar
  15. 15.
    Vestergaard ME, Macaskill P, Holt PE, Menzies SW (2008) Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 159:669–676PubMedGoogle Scholar
  16. 16.
    NCCN (2017) Clinical practice guidelines in oncology – melanoma version I.2018. National comprehensive cancer network. http:/NCCN.org. Zugegriffen: 27. Dez. 2017Google Scholar
  17. 17.
    Mills JK, White I, Diggs B, Fortino J, Vetto JT (2013) Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma. Am J Surg 205:585–590 (discussion 590)CrossRefGoogle Scholar
  18. 18.
    Pflugfelder A, Weide B, Eigentler TK, Forschner A, Leiter U, Held L, Meier F, Garbe C (2010) Incisional biopsy and melanoma prognosis: facts and controversies. Clin Dermatol 28:316–318CrossRefGoogle Scholar
  19. 19.
    Molenkamp BG, Sluijter BJ, Oosterhof B, Meijer S, van Leeuwen PA (2007) Non-radical diagnostic biopsies do not negatively influence melanoma patient survival. Ann Surg Oncol 14:1424–1430CrossRefGoogle Scholar
  20. 20.
    Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, Hollis S, Lens MB, Thompson JF (2009) Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD004835.pub2 CrossRefPubMedGoogle Scholar
  21. 21.
    Mocellin S, Pasquali S, Nitti D (2011) The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins. Ann Surg 253:238–243CrossRefGoogle Scholar
  22. 22.
    Wheatley K, Wilson JS, Gaunt P, Marsden JR (2016) Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation. Cancer Treat Rev 42:73–81CrossRefGoogle Scholar
  23. 23.
    Thomas JM, Newton-Bishop J, A’Hern R, Coombes G, Timmons M, Evans J, Cook M, Theaker J, Fallowfield M, O’Neill T, Ruka W, Bliss JM, United Kingdom Melanoma Study G, British Association of Plastic S, Scottish Cancer Therapy N (2004) Excision margins in high-risk malignant melanoma. N Engl J Med 350:757–766CrossRefGoogle Scholar
  24. 24.
    Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR, Wanebo HJ, Desmond R, Investigators from the Intergroup Melanoma Surgical T (2001) Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol 8:101–108PubMedGoogle Scholar
  25. 25.
    Gutzmer R, Frerich B, Krause-Bergmann A, Dippel E (2017) Ist eine komplette Lymphknotendissektion beim malignen Melanom mit positivem Sentinel notwendig? J Dtsch Dermatol Ges 15:1175–1176CrossRefGoogle Scholar
  26. 26.
    Kunte C, Geimer T, Baumert J, Konz B, Volkenandt M, Flaig M, Ruzicka T, Berking C, Schmid-Wendtner MH (2010) Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res 20:330–337CrossRefGoogle Scholar
  27. 27.
    Erman AB, Collar RM, Griffith KA, Lowe L, Sabel MS, Bichakjian CK, Wong SL, McLean SA, Rees RS, Johnson TM, Bradford CR (2012) Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer 118:1040–1047CrossRefGoogle Scholar
  28. 28.
    Parrett BM, Kashani-Sabet M, Singer MI, Li R, Thummala S, Fadaki N, Leong SP (2012) Long-term prognosis and significance of the sentinel lymph node in head and neck melanoma. Otolaryngol Head Neck Surg 147:699–706CrossRefGoogle Scholar
  29. 29.
    Erhebungsbogen für Hautkrebszentren der Deutschen Krebsgesellschaft (VersH1; 09102017j) http://www.onkozert.de/hauttumorzentren.htm. Zugegriffen: 17. Jan. 2018
  30. 30.
    Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkotter C, Kaatz M, Schulte KW, Lehmann P, Vogt T, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Martus P, Garbe C, German Dermatologic Cooperative Oncology G (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757–767CrossRefGoogle Scholar
  31. 31.
    Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters M, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:2211–2222CrossRefGoogle Scholar
  32. 32.
    Fritsch VA, Cunningham JE, Lentsch EJ (2016) Completion lymph node dissection based on risk of Nonsentinel metastasis in cutaneous melanoma of the head and neck. Otolaryngol Head Neck Surg 154:94–103CrossRefGoogle Scholar
  33. 33.
    Smith VA, Cunningham JE, Lentsch EJ (2012) Completion node dissection in patients with sentinel node-positive melanoma of the head and neck. Otolaryngol Head Neck Surg 146:591–599CrossRefGoogle Scholar
  34. 34.
    Eggermont AMM, Dummer R (2017) The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. Eur J Cancer 86:101–105CrossRefGoogle Scholar
  35. 35.
    Wevers KP, Bastiaannet E, Poos HP, van Ginkel RJ, Plukker JT, Hoekstra HJ (2012) Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites? Ann Surg Oncol 19:3913–3918CrossRefGoogle Scholar
  36. 36.
    O’Brien CJ, Gianoutsos MP, Morgan MJ (1992) Neck dissection for cutaneous malignant melanoma. World J Surg 16:222–226CrossRefGoogle Scholar
  37. 37.
    Medina JE, Ferlito A, Brandwein MS, Fisher SR, Pellitteri PK, Shaha AR, Pitman KT, Robbins KT, Rinaldo A, Silver CE, Byers RM, O’Brien CJ (2002) Current management of cutaneous malignant melanoma of the head and neck. Acta Otolaryngol 122:900–906CrossRefGoogle Scholar
  38. 38.
    Byers RM (1998) Treatment of the neck in melanoma. Otolaryngol Clin North Am 31:833–839CrossRefGoogle Scholar
  39. 39.
    Schmalbach CE, Johnson TM, Bradford CR (2006) The management of head and neck melanoma. Curr Probl Surg 43:781–835CrossRefGoogle Scholar
  40. 40.
    Reynolds HM, Smith NP, Uren RF, Thompson JF, Dunbar PR (2009) Three-dimensional visualization of skin lymphatic drainage patterns of the head and neck. Head Neck 31:1316–1325CrossRefGoogle Scholar
  41. 41.
    Wiener M, Uren RF, Thompson JF (2014) Lymphatic drainage patterns from primary cutaneous tumours of the forehead: refining the recommendations for selective neck dissection. J Plast Reconstr Aesthet Surg 67:1038–1044CrossRefGoogle Scholar
  42. 42.
    Geltzeiler M, Monroe M, Givi B, Vetto J, Andersen P, Gross N (2014) Regional control of head and neck melanoma with selective neck dissection. JAMA Otolaryngol Head Neck Surg 140:1014–1018CrossRefGoogle Scholar
  43. 43.
    Supriya M, Narasimhan V, Henderson MA, Sizeland A (2014) Managing regional metastasis in patients with cutaneous head and neck melanoma—is selective neck dissection appropriate? Am J Otolaryngol 35:610–616CrossRefGoogle Scholar
  44. 44.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A (2016) Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med 375:1845–1855CrossRefGoogle Scholar
  45. 45.
    Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF (2012) Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 13:589–597CrossRefGoogle Scholar
  46. 46.
    Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33:1191–1196CrossRefGoogle Scholar
  47. 47.
    Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889–1894CrossRefGoogle Scholar
  48. 48.
    Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbe C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J (2017) Overall survival with combined nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356CrossRefGoogle Scholar
  49. 49.
    Kunishige JH, Brodland DG, Zitelli JA (2012) Surgical margins for melanoma in situ. J Am Acad Dermatol 66:438–444CrossRefGoogle Scholar
  50. 50.
    DeBloom JR 2nd, Zitelli JA, Brodland DG (2010) The invasive growth potential of residual melanoma and melanoma in situ. Dermatol Surg 36:1251–1257CrossRefGoogle Scholar
  51. 51.
    Frerich B, Prall F (2018) Basalzellkarzinom der Gesichts- und Kopfhaut – Update der Therapieverfahren. Mkg-Chir 11:49–63CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik und Poliklinik für Mund‑, Kiefer- und Plastische GesichtschirurgieUniversitätsmedizin RostockRostockDeutschland

Personalised recommendations